TheraGenetics is collaborating with King’s College London to join the AddNeuroMed Consortium to identify biomarkers for Alzheimer’s disease. TheraGenetics will undertake a pharmacogenetic study of Alzheimer's patients treated with cholinesterase inhibitors in the study.
Cholinesterase inhibitors are a class of drugs approved to treat the cognitive symptoms of Alzheimer's disease. They prevent the breakdown of acetylcholine, a chemical in the brain that is important for learning and memory.
AddNeuroMed is part of InnoMed, an EFPIA sponsored study funded by the EU in partnership with the pharmaceutical industry and SMEs in Europe. AddNeuromed is designed to establish processes, tools, models, and cohorts for Alzheimer's disease biomarker discovery and validation.